SEARCH

SEARCH BY CITATION

References

  • 1
    Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:1119.
  • 2
    Sytkowski PA, D'Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation. 1996;93:697703.
  • 3
    Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the “rule of halves” still valid? J Hum Hypertens. 1997;11:213220.
  • 4
    Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353:20082013.
  • 5
    Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 6
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:17551762.
  • 7
    Zanchetti A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001;19:11491159.
  • 8
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383393.
  • 9
    Roman MJ, Saba PS, Pini R, et al. Parallel cardiac and vascular adaptation in hypertension. Circulation. 1992;86:19091918.
  • 10
    Cuspidi C, Lonati L, Macca G, et al. Cardiovascular risk stratification in hypertensive patients: impact of echocardiography and carotid ultrasonography. J Hypertens. 2001;19:375380.
  • 11
    Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963969.
  • 12
    Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J. 2002;23:528535.
  • 13
    Dolan E, Stanton A, Atkins N, et al. Determinants of whitecoat hypertension. Blood Press Monit. 2004;9:307309.
  • 14
    Pela G, Bruschi G, Cavatorta A, et al. Doppler tissue echocardiography: myocardial wall motion velocities in essential hypertension. Eur J Echocardiogr. 2001;2:108117.
  • 15
    Kanters SD, Elgersma OE, Banga JD, et al. Reproducibility of measurements of intima-media thickness and distensibility in the common carotid artery. Eur J Vase Endovasc Surg. 1998;16:2835.
  • 16
    Bots ML, Evans GW, Riley WA, et al. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke. 2003;34:29852994.
  • 17
    Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262269.
  • 18
    PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:10331041.
  • 19
    Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580586.
  • 20
    Cuspidi C, Ambrosioni E, Mancia G, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens. 2002;20:13071314.
  • 21
    Cuspidi C, Mancia G, Ambrosioni E, et al. Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the assessment prognostic risk observational survey (APROS). J Hum Hypertens. 2004;18:891896.
  • 22
    Vaudo G, Schillaci G, Evangelista F, et al. Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension. Am J Hypertens. 2000;13(4 pt 1):324331.
  • 23
    Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16(11 pts 1):895899.
  • 24
    Koren MJ, Ulin RJ, Koren AT, et al. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 2002;15:10211028.
  • 25
    Mancia G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control. Data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39:744749.
  • 26
    Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95110.
  • 27
    Tedesco MA, Ratti G, Aquino D, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens. 1998;12:505510.
  • 28
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 29
    Weir MR. Providing end-organ protection with reninangiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich). 2006;8:99105.
  • 30
    Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39:20052011.
  • 31
    Wang M, Yip GW, Wang AY, et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. J Hypertens. 2005;23:183191.
  • 32
    Bakris GL. Who should be treated with combination therapy as initial treatment for hypertension? J Clin Hypertens (Greenwich). 2003;5(4 suppl 3):2128.